A new review published in the open-access journal Ferroptosis and Oxidative Stress highlights Z-nucleic acid-binding protein 1 (ZBP1) as an emerging innate immune sensor that converts genomic stress into potent antitumor immunity, according to a Jul. 16 article. The authors propose that therapeutic activation of the ZBP1 pathway may transform immunologically "cold" tumors into "hot" tumors, offering new opportunities to overcome resistance to cancer immunotherapy.
In the article, "ZBP1-mediated sensing of genomic stress in cancer therapy," Dr. Xiao Zhong, Professor Siddharth Balachandran, and Professor Ting Zhang provide an overview of the rapidly evolving biology of ZBP1 and its role in cancer therapy. Originally recognized as an antiviral receptor, ZBP1 is now understood to function as a sensor of genomic and transcriptomic instability by recognizing Z-DNA and Z-RNA structures generated during endogenous retroelement activation, splicing stress, R-loop formation, viral mimicry, and other forms of cellular stress. The review synthesizes recent discoveries linking genomic stress sensing to regulated cell death and antitumor immune activation.
The authors describe how many tumors remain resistant because they fail to generate sufficient immune activation following treatment. They say that ZBP1 serves as a critical molecular checkpoint that detects stress-associated nucleic acids and initiates necroptosis—a highly inflammatory form of regulated cell death capable of stimulating robust antitumor immune responses. Rather than simply killing cancer cells, they write that "ZBP1-mediated necroptosis promotes the release of tumor antigens and damage-associated molecular patterns (DAMPs), creating conditions that enhance immune surveillance."
The review further explores how oxidative stress interacts with ZBP1 signaling. Upon activation, ZBP1 engages the RIPK1–RIPK3–MLKL signaling axis to trigger necroptosis, while reactive oxygen species both promote pathway activation and are amplified during necroptotic cell death. This interaction positions oxidative stress as both a regulator and amplifier of ZBP1-mediated immune signaling.
One central theme is the therapeutic potential for combining viral mimicry strategies with ZBP1 activation through treatments such as epigenetic modulators or splicing inhibitors—approaches designed to induce endogenous Z-form nucleic acids within tumors—and coupling these with localized ROS-generating methods or nanomedicine platforms for selective induction of immunogenic necroptosis within tumors.
The authors also discuss challenges before clinical translation can occur: identifying biomarkers for patient stratification by pathway activity; optimizing combination therapies; understanding tumor-specific regulation; and minimizing unwanted inflammatory toxicity.
